文献速递冠心病

急性冠脉综合征与非ACS左主干病变患者PCI与CABG的汇总分析

Percutaneous Coronary Intervention vs Coronary Artery Bypass Graft Surgery for Left Main Disease in Patients With and Without Acute Coronary Syndromes: A Pooled Analysis of 4 Randomized Clinical Trials.
PubMed 文献 · JAMA Cardiol · 2023-01-01

该研究汇总4项随机试验(SYNTAX、PRECOMBAT、NOBLE、EXCEL)的个体患者数据,比较PCI与CABG在左主干病变合并或不合并ACS患者中的临床结局。共纳入4394例患者,其中33%伴ACS。结果显示ACS患者30天全因死亡和心血管死亡风险更高,但5年全因死亡率在PCI与CABG间相似;PCI早期卒中风险较低,而5年自发性心肌梗死和再次血运重建风险较高,且不受ACS状态影响。

要点

  • ACS患者30天全因死亡风险显著高于非ACS患者(HR 3.40)。
  • 5年全因死亡率PCI与CABG在ACS和非ACS患者中均无显著差异。
  • PCI较CABG早期卒中风险低,但5年自发性MI和再次血运重建风险高。

核心结论

  • 在左主干病变患者中,ACS患者早期死亡风险更高,但5年全因死亡率PCI与CABG相似。
  • PCI与CABG在早期卒中和长期自发性MI及再次血运重建方面的相对优劣不受ACS状态影响。

研究设计与样本

  • 汇总4项随机临床试验(SYNTAX、PRECOMBAT、NOBLE、EXCEL)的个体患者数据。
  • 共纳入4394例左主干病变且被认为PCI与CABG均可行的患者,其中1466例(33%)伴ACS。
  • 采用Kaplan-Meier法计算5年事件率,Cox模型估计风险比,并检验交互作用。

主要发现

  • ACS患者30天全因死亡风险显著高于非ACS患者(HR 3.40;95%CI 1.81-6.37;P<.001)。
  • ACS患者30天心血管死亡风险亦更高(HR 3.21;95%CI 1.69-6.08;P<.001)。
  • ACS患者5年自发性MI风险较高(HR 1.70;95%CI 1.25-2.31;P<.001)。
  • 早期卒中风险PCI低于CABG(ACS:HR 0.39;95%CI 0.12-1.25;非ACS:HR 0.35;95%CI 0.16-0.75)。

临床怎么用

  • 对于左主干病变合并ACS的患者,PCI与CABG的5年生存率相似,但需权衡PCI较高的长期自发性MI和再次血运重建风险与较低的早期卒中风险。
  • ACS状态不影响PCI与CABG在早期卒中和长期自发性MI及再次血运重建方面的相对差异。

局限性

  • 研究人群主要为稳定患者且冠状动脉解剖复杂度以低至中等为主,结论可能不适用于更高危或复杂解剖患者。
  • 为汇总分析,非预设亚组分析,可能存在残余混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Patients with left main coronary artery disease presenting with an acute coronary syndrome (ACS) represent a high-risk and understudied subgroup of patients with atherosclerosis. OBJECTIVE: To assess clinical outcomes after PCI vs CABG in patients with left main disease with vs without ACS. DESIGN, SETTING, AND PARTICIPANTS: Data were pooled from 4 trials comparing PCI with drug-eluting stents vs CABG in patients with left main disease who were considered equally suitable candidates for either strategy (SYNTAX, PRECOMBAT, NOBLE, and EXCEL). Patients were categorized as presenting with or without ACS. Kaplan-Meier event rates through 5 years and Cox model hazard ratios were generated, and interactions were tested. Patients were enrolled in the individual trials from 2004 through 2015. Individual patient data from the trials were pooled and reconciled from 2020 to 2021, and the analyses pertaining to the ACS subgroup were performed from March 2022 through February 2023. MAIN OUTCOMES AND MEASURES: The primary outcome was death through 5 years. Secondary outcomes included cardiovascular death, spontaneous myocardial infarction (MI), procedural MI, stroke, and repeat revascularization. RESULTS: Among 4394 patients (median [IQR] age, 66 [59-73] years; 3371 [76.7%] male and 1022 [23.3%] female) randomized to receive PCI or CABG, 1466 (33%) had ACS. Patients with ACS were more likely to have diabetes, prior MI, left ventricular ejection fraction less than 50%, and higher SYNTAX scores. At 30 days, patients with ACS had higher all-cause death (hazard ratio [HR], 3.40; 95% CI, 1.81-6.37; P < .001) and cardiovascular death (HR, 3.21; 95% CI, 1.69-6.08; P < .001) compared with those without ACS. Patients with ACS also had higher rates of spontaneous MI (HR, 1.70; 95% CI, 1.25-2.31; P < .001) through 5 years. The rates of all-cause mortality through 5 years with PCI vs CABG were 10.9% vs 11.5% (HR, 0.93; 95% CI, 0.68-1.27) in patients with ACS and 11.3% vs 9.6% (HR, 1.19; 95% CI, 0.95-1.50) in patients without ACS (P = .22 for interaction). The risk of early stroke was lower with PCI vs CABG (ACS: HR, 0.39; 95% CI, 0.12-1.25; no ACS: HR, 0.35; 95% CI, 0.16-0.75), whereas the 5-year risks of spontaneous MI and repeat revascularization were higher with PCI vs CABG (spontaneous MI: ACS: HR, 1.74; 95% CI, 1.09-2.77; no ACS: HR, 3.03; 95% CI, 1.94-4.72; repeat revascularization: ACS: HR, 1.57; 95% CI, 1.19-2.09; no ACS: HR, 1.90; 95% CI, 1.54-2.33), regardless of ACS status. CONCLUSION AND RELEVANCE: Among largely stable patients undergoing left main revascularization and with predominantly low to intermediate coronary anatomical complexity, those with ACS had higher rates of early death. Nonetheless, rates of all-cause mortality through 5 years were similar with PCI vs CABG in this high-risk subgroup. The relative advantages and disadvantages of PCI vs CABG in terms of early stroke and long-term spontaneous MI and repeat revascularization were consistent regardless of ACS status. TRIAL REGISTRATION: ClinicalTrials.gov Identifiers: NCT00114972, NCT00422968, NCT01496651, NCT01205776.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Gaba, Christiansen, Nielsen, et al. Percutaneous Coronary Intervention vs Coronary Artery Bypass Graft Surgery for Left Main Disease in Patients With and Without Acute Coronary Syndromes: A Pooled Analysis of 4 Randomized Clinical Trials. JAMA Cardiol. 2023. PMID: 37256598. doi:10.1001/jamacardio.2023.1177

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。